Evidence map›Paper›PMID 38757975›Full record

ArticleMicrobiology spectrum2024

The whole genome sequence of Polish vaccine strain

Katarzyna Krysztopa-Grzybowska, Jakub Lach, Maciej Polak, Dominik Strapagiel, Jaroslaw Dziadek, Marcin Olszewski, Aleksandra A Zasada, Aniela Darlińska, Anna Lutyńska, Ewa Augustynowicz-Kopeć

Abstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katarzyna Krysztopa-GrzybowskaDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.ORCID 0000-0002-7332-5290
Jakub LachBiobank Lab, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Maciej PolakDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Dominik StrapagielBiobank Lab, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Jaroslaw DziadekMycobacterium Genetics and Physiology Unit, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.ORCID 0000-0003-1427-884X
Marcin OlszewskiChair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.
Aleksandra A ZasadaDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Aniela DarlińskaDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Anna LutyńskaDepartment of Medical Biology, National Institute of Cardiology, Warsaw, Poland.
Ewa Augustynowicz-KopećDepartment of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.

Funding

Narodowe Centrum Nauki (NCN) 2014/15/N/NZ7/03793
6 · The paper itself

Abstract

Currently, tuberculosis immunoprophylaxis is based solely on Bacillus Calmette-Guérin (BCG) vaccination, and some of the new potential tuberculosis vaccines are based on the BCG genome. Therefore, it is reasonable to analyze the genomes of individual BCG substrains. The aim of this study was the genetic characterization of the BCG-Moreau Polish (PL) strain used for the production of the BCG vaccine in Poland since 1955. Sequencing of different BCG lots showed that the strain was stable over a period of 59 years. As a result of comparison, BCG-Moreau PL with BCG-Moreau Rio de Janeiro (RDJ) 143 single nucleotide polymorphisms (SNPs) and 32 insertion/deletion mutations (INDELs) were identified. However, the verification of these mutations showed that the most significant were accumulated in the BCG-Moreau RDJ genome. The mutations unique to the Polish strain genome are 1 SNP and 2 INDEL. The strategy of combining short-read sequencing with long-read sequencing is currently the most optimal approach for sequencing bacterial genomes. With this approach, the only available genomic sequence of BCG-Moreau PL was obtained. This sequence will primarily be a reference point in the genetic control of the stability of the vaccine strain in the future. The results enrich knowledge about the microevolution and attenuation of the BCG vaccine substrains. IMPORTANCE: The whole genome sequence obtained is the only genomic sequence of the strain that has been used for vaccine production in Poland since 1955. Sequencing of different BCG lots showed that the strain was stable over a period of 59 years. The comprehensive genomic analysis performed not only enriches knowledge about the microevolution and attenuation of the BCG vaccine substrains but also enables the utilization of identified markers as a reference point in the genetic control and identity tests of the stability of the vaccine strain in the future.

Indexed as

BCG VaccineGenome, BacterialMycobacterium bovisPolymorphism, Single NucleotideWhole Genome SequencingHumansINDEL MutationMutationPolandTuberculosisBCG VaccineBCG MoreauBCG Moreau PLBCG vaccinecomplete genomic sequencenext-generation sequencingtuberculosis

Identifiers

PMID38757975
PMCPMC11237378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.